CJC-1295 (No DAC) + GHRP-6 | Pen

CJC-1295 (No DAC) + GHRP-6 is a blend positioned for controlled research settings where pulsatile growth hormone signaling is being studied in relation to GH/IGF-1 biomarker dynamics, body composition endpoints, and recovery- and sleep-linked physiology markers.

Supports

1. Pituitary GH pulse amplitude and frequency endpoints (model-dependent)
2. IGF-1 biomarker tracking as a downstream axis readout (endpoint-dependent)
3. Substrate utilization and body composition marker panels in metabolic models
4. Sleep-architecture and recovery-associated signaling proxies (context-dependent)
5. Appetite and ghrelin-pathway behavioral readouts in controlled models (GHSR-linked)

Description

CJC-1295 (No DAC) + GHRP-6 combines two peptide classes commonly used to study growth hormone (GH) physiology from complementary angles. CJC-1295 (No DAC), also referred to as a stabilized GHRH (growth hormone-releasing hormone) analog, is positioned to explore pituitary receptor signaling that promotes GH release. GHRP-6 is a growth hormone secretagogue peptide studied for ghrelin receptor (GHSR) agonism and GH pulse facilitation.

In experimental designs, the blend is often framed as a “dual-pathway” approach: a GHRH-analog signal that supports pituitary GH release biology, paired with a GHSR-agonist signal that can modulate pulse characteristics and associated behavioral/metabolic markers. Research outcomes are typically evaluated through time-resolved GH and IGF-1 biomarkers, metabolic endpoints (lipid oxidation and glucose handling proxies), and recovery-linked readouts such as sleep or training-stress adaptation markers, depending on the model.

Because GH-axis outputs can vary with baseline endocrine state, sampling strategy, and assay design, interpretation is usually endpoint-driven and paired with structured controls (baseline hormone panels, serial sampling, and standardized challenge conditions where applicable).

Clinical Status

This blend is positioned for research use. Human evidence exists for GH secretagogues and GHRH-analog pharmacology in selected contexts, while many mechanistic claims are most robustly supported by controlled endocrine physiology literature and preclinical models. The combination itself is best interpreted through biomarker-driven endpoints rather than generalized outcome claims.

Evidence type:
Human RCT ☐ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

CJC-1295 (No DAC) is used as a GHRH-analog input to study signaling at the pituitary GHRH receptor, which can promote GH secretion under controlled conditions. GHRP-6 is studied as a ghrelin receptor (GHSR) agonist, a pathway known to influence GH release patterns and appetite-linked signaling in many experimental paradigms.

When combined, experimental designs may examine whether concurrent GHRH-receptor signaling and GHSR signaling produces additive or synergistic changes in GH pulse profiles and downstream IGF-1 readouts. Mechanistic assessment typically includes serial hormone sampling (GH pulses), downstream biomarker monitoring (IGF-1), and secondary endpoints such as metabolic readouts (substrate utilization proxies) and sleep/recovery markers where relevant.

Benefits

• Dual-pathway GH-axis modeling:
  Supports studies evaluating GH secretion biology via combined GHRH-receptor and GHSR-linked signaling inputs.
• Time-resolved endocrine biomarker tracking:
  Enables protocols focused on serial GH sampling and downstream IGF-1 biomarker dynamics (model-dependent).
• Metabolic endpoint integration:
  Relevant to designs examining substrate utilization, lipid handling, and glucose regulation proxies alongside GH-axis markers.
• Recovery and sleep-related physiology markers:
  Supports exploratory work where sleep architecture or recovery-associated signals are studied in relation to GH pulsatility.
• Appetite and neuroendocrine signaling readouts:
  GHSR agonism is often paired with behavioral and appetite-related endpoints in controlled models (context-dependent).
• Experimental controllability without direct GH replacement:
  Positions GH-axis modulation as an upstream signaling study approach, emphasizing biomarker-defined outputs and controls.

Research Data

Stack Suggestions

In extended experimental designs, CJC-1295 (No DAC) + GHRP-6 is sometimes paired with:

• IGF-1 LR3 → to compare upstream GH-axis modulation with direct IGF-axis endpoint frameworks
• SS-31 (Elamipretide) → to add mitochondrial resilience readouts alongside recovery-linked biomarker panels
• AICAR → to integrate AMPK-linked metabolic switching endpoints with GH/IGF biomarker tracking

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

No product-specific adverse-effect text was provided. In research contexts involving GH secretagogues and ghrelin-pathway agonism, model-dependent observations can include appetite-related effects, transient changes in water balance markers, shifts in glucose-related biomarkers, and injection-site reactions (redness, sensitivity, mild swelling). Endocrine outputs and tolerability signals can vary by baseline physiology and protocol duration, so controlled monitoring of biomarkers and discontinuation upon sensitivity signals are standard experimental precautions.

Scientific References

• GHRH receptor signaling and pituitary GH release mechanisms (PubMed search) — Review
• Mod GRF (1-29) / CJC-1295 (No DAC) pharmacology and endocrine endpoints (PubMed search) — In vitro/Animal
• GHRP-6 as a growth hormone secretagogue: endocrine physiology endpoints (PubMed search) — In vitro/Animal
• Ghrelin receptor (GHSR) agonism and GH release biology (PubMed search) — Review
• Growth hormone pulsatility and serial sampling methodology (PubMed search) — Review
• IGF-1 as a downstream biomarker of GH-axis activity (PubMed search) — Review
• Sleep architecture and nocturnal growth hormone pulse physiology (PubMed search) — Review
• Ghrelin receptor agonism and appetite/feeding behavior endpoints (PubMed search) — Animal
• Growth hormone secretagogues: mechanisms, biomarkers, and model considerations (PubMed search) — Review
• GHRH analog + ghrelin agonist combination designs and GH-axis endpoint outcomes (PubMed search) — Animal/In vitro

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.